ATLANTA – The anti-PD-1 monoclonal antibody pembrolizumab (Keytruda) showed promising antitumor activity with durable responses in patients with pretreated,...
ATLANTA – The investigational therapeutic umbralisib, which targets the molecule PI3K-delta, was well tolerated and highly active in patients...
“ATLANTA – Vaccination with as few as four tumor antigens generated antigen-specific responses, reduced intestinal tumors, and improved survival...
“ATLANTA – Treatment with the FLT3-targeted therapeutic gilteritinib (Xospata) improved survival for patients with relapsed or refractory acute myeloid...
PHILADELPHIA – The American Association for Cancer Research (AACR) recognized Emil J Freireich, MD, FAACR, with the 2019 AACR...
ATLANTA – Excess weight before age 50 may be more strongly associated with pancreatic cancer mortality risk than excess...
ATLANTA – A chimeric antigen receptor (CAR) T-cell therapy that targets the protein mesothelin showed no evidence of major...
ATLANTA – A combination of chemotherapy and chimeric antigen receptor (CAR) T cells designed to target the protein HER2...
ATLANTA – A combination of the anti-CTLA-4 immunotherapeutic ipilimumab (Yervoy) and the anti-PD-1 immunotherapeutic nivolumab (Opdivo) showed clinical benefit...
ATLANTA – Adding the investigational MET inhibitor savolitinib to the EGFR inhibitor osimertinib (Tagrisso) yielded clinical responses in patients...